Aclaris Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACRS Nasdaq 8731 https://www.aclaristx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclaris Therapeutics Inc

Aclaris Therapeutics Provides 2023 Outlook - Jan 6th, 2023 12:01 pm
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China - Nov 29th, 2022 12:00 pm
Lab Notes: Biotech firm bioMerieux unveils new product for detecting spoiled wine - Nov 26th, 2022 6:39 pm
Aclaris Therapeutics Announces Key Leadership Transitions - Nov 22nd, 2022 9:01 pm
Aclaris Therapeutics Looks Promising on the Charts - Nov 16th, 2022 5:10 pm
Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences - Nov 10th, 2022 9:01 pm
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - Nov 8th, 2022 1:25 pm
Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update - Nov 8th, 2022 12:00 pm
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely - Oct 26th, 2022 10:44 am
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations - Sep 27th, 2022 11:00 am
Aclaris Therapeutics (NASDAQ:ACRS) pulls back 7.4% this week, but still delivers shareholders massive 110% CAGR over 3 years - Sep 15th, 2022 10:46 am
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Aug 30th, 2022 11:00 am
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata - Aug 25th, 2022 11:00 am
Health Check: How Prudently Does Aclaris Therapeutics (NASDAQ:ACRS) Use Debt? - Aug 5th, 2022 11:59 am
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates - Aug 3rd, 2022 12:25 pm
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update - Aug 3rd, 2022 11:00 am
Aclaris Therapeutics Expands Leadership Team - Aug 1st, 2022 11:00 am
Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy - Jul 15th, 2022 4:00 pm
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? - Jul 8th, 2022 1:40 pm
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? - Jun 22nd, 2022 1:40 pm